GlassScriptPhysician profile
Andrey Manov
NPI 1801829676
$2,439.65
in general payments reported to CMS, 2019-2025
30 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $80.75 · 2021: $205 · 2022: $270 · 2023: $168 · 2024: $544 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.46 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $438.49 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $238.11 | 2023-2025 | Repatha, Prolia, Evenity |
| Pfizer INC. | $188.17 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.46 | 2024-2025 | Airsupra |
| Chiesi USA, INC. | $146.96 | 2025 | Mycapssa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.75 | 2021-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $122.90 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $118.75 | 2020-2025 | Eliquis |
| Mannkind Corporation | $86.48 | 2025 | |
| Intuitive Surgical, INC. | $82.04 | 2024 | |
| Madrigal Pharmaceuticals | $78.03 | 2025 | Rezdiffra |
| Abbott Laboratories | $73.22 | 2021-2022 | |
| Lilly USA, LLC | $60.35 | 2021-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $58.75 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $51.01 | 2025 | Yorvipath |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $40.33 | 2019-2024 | Omnipod |
| Astellas Pharma US INC | $36.46 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.11 | 2023-2024 | Jardiance, Synjardy |
| Medtronic, INC. | $31.09 | 2024 | Minimed 780g |
| Boston Scientific Corporation | $30.36 | 2025 | General - Pain Management |
| Companion Medical, INC. | $29.10 | 2019 | |
| Kyowa Kirin, INC. | $28.71 | 2025 | |
| Sanofi-Aventis U.S. LLC | $28.63 | 2024 | |
| Medtronic Minimed, INC. | $23.66 | 2019 | |
| Corcept Therapeutics | $20.39 | 2019 | |
| Exact Sciences Corporation | $18.84 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2024 | |
| Si-Bone, INC. | $16.63 | 2020 | |
| Valeritas, INC. | $15.42 | 2019 | |
| Merck Sharp & Dohme LLC | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrey Manov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.